Search results
Results from the WOW.Com Content Network
The StomaphyX device can be used to restrict the size of the stoma without exposing the patient to further surgical risk. [1] Although initial post-procedure weight loss is evident in some trials, there is doubt as to whether such results are sustained over the long term. [2] The StomaphyX device was patented by EndoGastric Solutions.
The long-term mortality rate of gastric bypass patients has been shown to be reduced by up to 40%. [journal 1] [journal 2] As with all surgery, complications may occur. A study from 2005 to 2006 revealed that 15% of patients experienced complications as a result of gastric bypass, and 0.5% of patients died within six months of surgery due to ...
The first patient was treated using the Edmonton protocol in March 1999. The protocol was first published in the New England Journal of Medicine in July 2000. [1] The NEJM report was exciting for the diabetes field because the seven patients undergoing the Edmonton protocol remained insulin-independent after an average of 12 months. [citation ...
Bariatric surgery has proven to be the most effective obesity treatment option for enduring weight loss. [17] Along with this weight reduction, the procedure reduces risk of cardiovascular diseases, type 2 diabetes, fatty liver disease, depression syndromes, among others. [18]
Type 1 diabetes, also known as juvenile diabetes, is a condition in which the body does not produce insulin, resulting in high levels of sugar in the bloodstream. [1] [2] Whereas type 2 diabetes is typically diagnosed in middle age and treated via diet, oral medication and/or insulin therapy, type 1 diabetes tends to be diagnosed earlier in life, and people with type 1 diabetes require insulin ...
The SADI-S is a single anastomosis bariatric surgery. It is different from the classic duodenal switch, the gastric bypass (RNY) or sleeve gastrectomy.It is a type of bariatric surgery carried out to lose weight and to mitigate various metabolic issues including type 2 diabetes, dislipidemia, metabolic syndrome, and polycystic ovary syndrome.
Austin, TX, USA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neurostimulation Device Market Size, Trends and Insights By Product (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Electric Stimulator), By Application (Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal ...
So far as macrovascular disease in type 1 diabetes is concerned, the same group reported improved outcomes for cardiovascular events in the group who had been managed by strict blood glucose control: in this group the incidence of any cardiovascular disease was reduced by 30% (95% CI 7, 48; P = 0.016) compared to the group with less intensive ...